Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia
Acute Lymphoblastic LeukemiaThe purpose of the study is to determine the utility of XCL1 in the prognosis of acute lymphoblastic leukemia.
Studying Biomarkers as a Diagnostic Tool in Samples From Younger Patients With B-Cell Acute Lymphoblastic...
B-cell Childhood Acute Lymphoblastic LeukemiaChildhood Acute Lymphoblastic Leukemia in Remission1 moreThis clinical trial is studying biomarkers as a diagnostic tool in samples from younger patients with B-cell acute lymphoblastic leukemia. Finding specific biomarkers may help improve the treatment of patients with B-cell acute lymphoblastic leukemia
Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children
Acute Lymphoblastic LeukemiaAcute Myeloblastic Leukemia3 moreThe aim of this study was to investigate the occurrences of respiratory symptoms risk factors and abnormalities in lung function in young children (3-6 years old) with hemato-oncologic diseases at presentation (before treatment) and up to 3 years follow-up (study period).
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
Childhood B Acute Lymphoblastic LeukemiaChildhood T Acute Lymphoblastic Leukemia5 moreThis clinical trial is looking at brain function in young patients receiving methotrexate for acute lymphoblastic leukemia. Learning about the long-term effects of methotrexate on brain function may help doctors plan cancer treatment.
Neurobehavioral Complications in Children Who Were Previously Treated With Steroids and Intrathecal...
LeukemiaLong-term Effects Secondary to Cancer Therapy in Children2 moreRATIONALE: Cancer therapies may affect the ability of a child's brain and central nervous system to function normally. Learning to identify which patients will develop complications may improve the ability of doctors to plan cancer treatment and improve patient quality of life. PURPOSE: This clinical trial is studying neurobehavioral changes in children who have received steroid therapy or intrathecal therapy for acute lymphoblastic leukemia.
Health Care Utilisation Among Survivors of Childhood Acute Lymphoblastic Leukaemia
Precursor Cell Lymphoblastic Leukemia-LymphomaImproved understanding of the long-time healthcare utilisation of childhood cancer survivors is relevant as it can be seen as a proxy for the population's morbidity. The investigators will conduct a historic population-based matched cohort study using Danish nationwide registry data. Eligible children are children 1.0-17.9 years diagnosed with Acute lymphoblastic leukaemia (ALL) in Denmark from 1994 till 2016. The primary outcome is yearly contact rates to primary healthcare.
A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic...
CLLThe aim of this study is to evaluate the impact of Ibrutinib monotherapy in the QoL of subjects with Chronic Lymphocytic Leukemia (CLL) based in European Quality of Life 5 Dimensions (EQ-5D) and FACIT- fatigue questionnaires assessment from baseline to 1 year of treatment in Argentinian routine clinical practice.
Latin American Real-world Study in Acute Leukemia
Acute Myeloid LeukemiaAcute Lymphoid LeukemiaThe objective of the study is to describe the current epidemiology, treatment patterns, outcomes and healthcare resource use of adult patients diagnosed with relapsed/refractory (R/R) B-cell ALL and de novo AML in 4 Latin American countries.
A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia
Chronic Lymphocytic LeukemiaThis project addresses the need to improve physician knowledge and clinical practice patterns related to quality of life (QoL) concerns for patients with chronic lymphocytic leukemia (CLL).
Observational Study in CLL Patients Receiving BR
Chronic Lymphocytic LeukemiaThe purpose of this observational study is to provide additional data to confirm the safety profile and efficacy of bendamustine and rituximab (BR) chemotherapy for chronic lymphocytic leukemia patients with significant comorbidities treated in routine clinical practice.